Gelesis Presents Expanded Data Showing Impact of Gelesis100 Hydrogel on Patients with Prediabetes, Untreated Diabetes, ...
(WorldNews Business)

BOSTON--(BUSINESS WIRE)--Mar 25, 2019--, a biotechnology company developing first-in-class mechanotherapeutics to treat obesity and other chronic diseases related to the gastrointestinal (GI) pathway, today announced clinical data from its pivotal GLOW study suggesting that elevated fasting plasma glucose could be a useful and unique predictor to identify individuals who have higher adjusted odds to achieve significant weight loss with Gelesis100. As observed in a previous pilot study, participants with prediabetes or untreated type 2 diabetes were particularly responsive to its lead product candidate for weight management, Gelesis100. In addition, participants with high insulin resistance...